| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiu Luo, Linlin Pan, Aifang Nie, Qidi Wang, Yanyun Gu, Fengying Li, Hongli Zhang, Wenyi Li, Xiaoying L. Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats. Journal of diabetes. vol 5. issue 4. 2014-07-01. PMID:23590680. |
glucagon-like peptide-1 (glp-1) analogues have emerged as insulin secretagogues and are widely used in type 2 diabetic patients. |
2014-07-01 |
2023-08-12 |
rat |
| Mathieu Weitten, Jean-Patrice Robin, Hugues Oudart, Paul Pévet, Caroline Habol. Hormonal changes and energy substrate availability during the hibernation cycle of Syrian hamsters. Hormones and behavior. vol 64. issue 4. 2014-07-01. PMID:24005184. |
our study aims to define these metabolic adaptations, including hormone (insulin, glucagon, leptin, adiponectin, glp-1, gip) and metabolite (glucose, free fatty acids, triglycerides, urea) profiles together with body composition adjustments. |
2014-07-01 |
2023-08-12 |
Not clear |
| Jamie Eugene Mells, Frank A Anani. The role of gastrointestinal hormones in hepatic lipid metabolism. Seminars in liver disease. vol 33. issue 4. 2014-07-01. PMID:24222092. |
although glp-1 is a clinically relevant pharmacological analogue that drives pancreatic β-cell insulin output, glp-1 analogues also have independent benefits via their effects on hepatocellular ffa metabolism. |
2014-07-01 |
2023-08-12 |
human |
| Yu-Ting Alex Chiang, Wilfred Ip, Weijuan Shao, Zhuolun Eric Song, Jonathan Chernoff, Tianru Ji. Activation of cAMP signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice. Endocrinology. vol 155. issue 6. 2014-06-30. PMID:24684301. |
p21-activated protein kinase-1 (pak1) plays a role in insulin secretion and glucagon-like peptide-1 (glp-1) production. |
2014-06-30 |
2023-08-12 |
mouse |
| Yan Yang, Jing Zhang, Delin Ma, Muxun Zhang, Shuhong Hu, Shiying Shao, Cheng-Xin Gon. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. Journal of Alzheimer's disease : JAD. vol 37. issue 3. 2014-06-27. PMID:23948890. |
here we studied whether liraglutide, an agonist of glucagon-like peptide-1 (glp-1) and a new anti-diabetic drug, can promote brain insulin signaling and inhibit tau hyperphosphorylation in the brains of type 2 diabetic rats. |
2014-06-27 |
2023-08-12 |
rat |
| Nina Sauer, Thomas Rösch, Jennifer Pezold, Franziska Reining, Mario Anders, Stefan Groth, Guido Schachschal, Oliver Mann, Jens Aberl. A new endoscopically implantable device (SatiSphere) for treatment of obesity--efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obesity surgery. vol 23. issue 11. 2014-06-24. PMID:23780702. |
a new endoscopically implantable device (satisphere) for treatment of obesity--efficacy, safety, and metabolic effects on glucose, insulin, and glp-1 levels. |
2014-06-24 |
2023-08-12 |
Not clear |
| Xiao Feng, Shuzhe Zhong, Jian Yang, Yong Wang, Jingang Li. Effects on glucagon-like peptide-1 secretion by distal ileal administration of nutrients. Obesity surgery. vol 23. issue 11. 2014-06-24. PMID:23873128. |
the aim of this study was to investigate the effects of nutrients (glucose, fat, and amino acid) on glucagon-like peptide-1 (glp-1) secretion by the l cell in the distal ileum and insulin level in peripheral blood. |
2014-06-24 |
2023-08-12 |
Not clear |
| Maria Grazia Magro, Michele Solimen. Regulation of β-cell function by RNA-binding proteins. Molecular metabolism. vol 2. issue 4. 2014-06-24. PMID:24327951. |
elevation of extracellular glucose and/or glp-1 levels triggers a rapid upregulation of insulin biosynthesis through the activation of post-transcriptional mechanisms. |
2014-06-24 |
2023-08-12 |
Not clear |
| Young Min Cho, Rhonda D Wideman, Timothy J Kieffe. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinology and metabolism (Seoul, Korea). vol 28. issue 4. 2014-06-24. PMID:24396690. |
glucagon-like peptide 1 (glp-1) is secreted from enteroendocrine l-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. |
2014-06-24 |
2023-08-12 |
Not clear |
| John Geric. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International journal of general medicine. vol 6. 2014-06-24. PMID:24403842. |
this article reviews the pathogenesis of postprandial hyperglycemia, the mechanisms by which glp-1 receptor agonists and dpp-4 inhibitors reduce postprandial plasma glucose concentrations, and the results of recent clinical trials (ie, published 2008 to october 2012) that evaluated the effects of these agents on postprandial plasma glucose levels when evaluated as monotherapy compared with placebo or as add-on therapy to metformin, a sulfonylurea, or insulin. |
2014-06-24 |
2023-08-12 |
Not clear |
| John Geric. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International journal of general medicine. vol 6. 2014-06-24. PMID:24403842. |
findings from recent clinical studies suggest that both glp-1 receptor agonists and dpp-4 inhibitors could become valuable treatment options for optimizing glycemic control in patients unable to achieve glycated hemoglobin goals on basal insulin, with the added benefits of weight loss and a low risk of hypoglycemia. |
2014-06-24 |
2023-08-12 |
Not clear |
| Bo Ahré. Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World journal of diabetes. vol 5. issue 1. 2014-06-24. PMID:24567800. |
there are many advantages of combining incretin therapy [glucagon-like peptide-1 (glp-1) receptor agonists and dipeptidyl peptidase-4 (dpp-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. |
2014-06-24 |
2023-08-12 |
Not clear |
| Bo Ahré. Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World journal of diabetes. vol 5. issue 1. 2014-06-24. PMID:24567800. |
several clinical trials have studied the addition of glp-1 receptor agonists [exenatide bid (twice daily), lixisenatide, albiglutide] or dpp-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a glp-1 receptor agonist (liraglutide). |
2014-06-24 |
2023-08-12 |
Not clear |
| Yutaka Seino, Mitsuo Fukushima, Daisuke Yab. GIP and GLP-1, the two incretin hormones: Similarities and differences. Journal of diabetes investigation. vol 1. issue 1-2. 2014-06-24. PMID:24843404. |
gastric inhibitory polypeptide (gip) and glucagon-like peptide-1 (glp-1) are the two primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells. |
2014-06-24 |
2023-08-13 |
human |
| Yutaka Seino, Daisuke Yab. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. Journal of diabetes investigation. vol 4. issue 2. 2014-06-24. PMID:24843641. |
glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) are the two primary incretin hormones secreted from the intestine on ingestion of various nutrients to stimulate insulin secretion from pancreatic β-cells glucose-dependently. |
2014-06-24 |
2023-08-13 |
mouse |
| Jens Juul Hols. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Current opinion in pharmacology. vol 13. issue 6. 2014-06-19. PMID:24161809. |
surgery is also associated with dramatic increases in the secretion of the gut hormones, glucagon-like peptide-1 (glp-1) and peptide yy (pyy), both of which regulate appetite and food intake, while glp-1 in addition functions as an incretin hormone, stimulating insulin secretion. |
2014-06-19 |
2023-08-12 |
Not clear |
| Jens Juul Hols. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Current opinion in pharmacology. vol 13. issue 6. 2014-06-19. PMID:24161809. |
it has been possible to probe the role of glp-1 for the diabetes resolution after gastric bypass using a glp-1 receptor antagonist, and it is clear that the enhanced beta cell sensitivity to glucose which underlies the enhanced insulin secretion in the patients after the operation depends critically on the increased glp-1 secretion. |
2014-06-19 |
2023-08-12 |
Not clear |
| S Vasu, R C Moffett, J T McCluskey, M H Hamid, N Irwin, P R Flat. Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice. Gene therapy. vol 20. issue 11. 2014-06-17. PMID:23784442. |
circulating glucose (p<0.01) and glucagon (p<0.05) were significantly reduced and plasma insulin and glp-1 dramatically increased. |
2014-06-17 |
2023-08-12 |
mouse |
| D R Owens, L Monnier, G B Boll. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes & metabolism. vol 39. issue 6. 2014-06-17. PMID:24156868. |
metabolic consequences of glucagon-like peptide-1 receptor agonists (glp-1 ras) are the result of enhanced glucose-stimulated insulin secretion, inhibition of glucagon release, delayed gastric emptying and increased satiety. |
2014-06-17 |
2023-08-12 |
human |
| D R Owens, L Monnier, G B Boll. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes & metabolism. vol 39. issue 6. 2014-06-17. PMID:24156868. |
evidence suggests that the glp-1 ras that predominantly target the prandial glucose excursions, such as exenatide twice daily and lixisenatide once-daily prandial, are therefore best used as combination therapy with basal insulin and will form an important new treatment option for individuals with t2dm. |
2014-06-17 |
2023-08-12 |
human |